A Stanford study found that COVID-19 vaccines generate antibodies that are more capable of recognizing viral variants than are those created by natural infection. Credit: Steve Fisch |
Antibodies generated by COVID-19 vaccines are more suited to recognizing viral variants than antibodies that arise from natural infection, according to a study by researchers at Stanford Medicine.
A key finding of the study might explain why: Regions in lymph nodes known as germinal centers — where antibodies are chosen and amplified by the immune system — are highly active for several weeks after vaccination. In contrast, the structure and cell composition of germinal centers are profoundly disrupted in people with fatal cases of COVID-19.
“Vaccination generates a range of antibodies capable of responding to viral antigens beyond the original exposure,” said Scott Boyd, MD, PhD, associate professor of pathology. “This greater breadth of antibodies suggests that vaccination is likely to be more protective against viral variants than immunity generated by previous infection.”
Boyd shares a senior authorship of the study, which was published in Cell, with Kari Nadeau, MD, PhD, the Naddisy Foundation Professor in Pediatric Food Allergy, Immunology, and Asthma. The lead authors are postdoctoral scholar Katharina Röltgen, PhD; former postdoctoral scholar Sandra Nielsen, PhD; clinical assistant professor of pathology Oscar Silva, MD, PhD; and life science researcher Sheren Younes, MD, PhD.